{
    "score": [
        0.7692307692307693
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "stemline therapeutics inc given consensus recommendation of `` hold '' by analysts ."
    ],
    "id": "426964.train",
    "article": [
        "shares of stemline therapeutics inc have been assigned a consensus rating of `` hold '' from the eight research firms that are currently covering the stock , marketbeat ratings reports . three analysts have rated the stock with a sell rating and five have issued a buy rating on the company . the average 1-year target price among brokerages that have covered the stock in the last year is $ 33.75 . stml has been the subject of a number of research analyst reports . hc wainwright reaffirmed a `` buy '' rating and issued a $ 38.00 price target on shares of stemline therapeutics in a research note on friday , november 10th . ",
        "cowen reaffirmed a `` buy '' rating on shares of stemline therapeutics in a research note on tuesday , october 31st . finally , bidaskclub lowered shares of stemline therapeutics from a `` buy '' rating to a `` hold '' rating in a research note on thursday , december 7th . in other news , coo kenneth hoberman sold 11,943 shares of the company 's stock in a transaction that occurred on friday , december 15th . the shares were sold at an average price of $ 14.18 , for a total value of $ 169,351.74 . the sale was disclosed in a document filed with the securities & exchange commission , which is available through this link . ",
        "corporate insiders own 16.70 % of the company 's stock . several large investors have recently modified their holdings of stml . voya investment management llc acquired a new stake in stemline therapeutics during the second quarter valued at approximately $ 102,000 . nationwide fund advisors lifted its stake in stemline therapeutics by 7.2 % during the second quarter . nationwide fund advisors now owns 12,755 shares of the biopharmaceutical company 's stock valued at $ 117,000 after purchasing an additional 855 shares during the last quarter . state of wisconsin investment board acquired a new stake in stemline therapeutics during the second quarter valued at approximately $ 147,000 . ",
        "the manufacturers life insurance company lifted its stake in stemline therapeutics by 40.1 % during the second quarter . the manufacturers life insurance company now owns 19,279 shares of the biopharmaceutical company 's stock valued at $ 178,000 after purchasing an additional 5,522 shares during the last quarter . finally , alliancebernstein l. p. acquired a new stake in stemline therapeutics during the second quarter valued at approximately $ 178,000 . 50.24 % of the stock is owned by institutional investors . shares of stemline therapeutics opened at $ 13.90 on tuesday . the firm has a market cap of $ 357.93 , a p/e ratio of -5.41 and a beta of -0.02 . ",
        "stemline therapeutics has a one year low of $ 5.50 and a one year high of $ 16.00 . illegal activity warning : this article was first reported by american banking news and is owned by of american banking news . if you are accessing this article on another publication , it was illegally copied and republished in violation of international copyright and trademark law . the original version of this article can be accessed at therapeutics company profilestemline therapeutics , inc is a clinical-stage biopharmaceutical company focused on discovering , acquiring , developing and commercializing oncology therapeutics . the company is developing approximately three clinical stage product candidates , including sl-401 , sl-701 and sl-801 . ",
        "sl-401 is a targeted therapy directed to the interleukin-3 receptor , present on a range of hematologic cancers . receive news & ratings for stemline therapeutics daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for stemline therapeutics and related companies with marketbeat . com 's free daily email newsletter .   "
    ]
}